TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01372631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miniature spectral imaging system
Description: Use of miniature spectral imaging system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miniature spectral imaging system
Description: Use of miniature spectral imaging system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miniature spectral imaging system
Description: Use of miniature spectral imaging system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bench-top optical spectrometer
Description: Use of bench-top optical spectrometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bench-top optical spectrometer
Description: Use of bench-top optical spectrometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bench-top optical spectrometer
Description: Use of bench-top optical spectrometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High resolution microendoscope
Description: Use of high resolution microendoscope
Study: NCT01234597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSULIN GLARGINE (HOE901)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE (HOE901)
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSULIN GLULISINE (HMR1964)
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE (HMR1964)
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
Study: NCT01836562

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: STEM CELL THERAPY
Description: Intra thecal injection of autologous MNC ,Intra thecal inj.of 100 millions MNC in 3 doses at 10 days interval.
Study: NCT02126215

Intervention type: PROCEDURE
Intervention: MRI CO2 and O2 stress testing
Description: Pre and post operatively
Study: NCT01442662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib + gemcitabine
Description: pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
Study: NCT00954265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10000 IU urinary HCG
Description: ovulation triggering

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mcg recombinant HCG
Description: ovulation triggering
Study: NCT03021980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SuperFIT
Description: Behavioural intervention with two components. One component will consist of social and physical environmental changes at the preschools and the other component consists of a family educational program.
Study: NCT00168389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
Study: NCT03895359

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation
Description: For patients randomized to the SMRT arm, SBRT is to be delivered over 5 fractions delivered over 5 to 15 days.
Study: NCT03895359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization
Description: Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.
Study: NCT01715948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CROS hearing aid
Description: Participants were randomly assigned to be fitted with the CROS hearing aid either at the end of the first visit or at the end of the second visit. They were given a 2-week trial with the CROS and asked to refrain from wearing their BAHD during that time. At the end of the first visit, four participants were fitted with the CROS hearing aid and were subsequently tested with this device on their second visit, at which time they were instructed to use the BAHD for the next 2 weeks. This protocol was reversed in the other four participants, with testing after each device experience. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone-anchored hearing device (BAHD)
Description: All participants had received BAHD implantation prior to the study. They were randomly selected to continue wearing their BAHD for 2 weeks following the end of the first visit or the end of the second visit. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
Study: NCT05332314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDs
Description: The patients will be given NSAIDs with a reduced dose of the standard opioids treatment.
Study: NCT00168389

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
Study: NCT01607879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care ADT + (HMB + arginine + glutamine)
Description: 1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.~Take one packet twice daily for 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care ADT
Description: Patient will receive standard of care androgen deprivation therapy (ADT) alone
Study: NCT00447668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga for back pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: exercises for back pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care book recommendations
Description: Self-care book for back pain
Study: NCT04292210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perisafe
Description: A medical device simplifying the connection of tubing as well as breaking of the frangible which is done in a sterile environment with the help of levers and buttons.
Study: NCT04329429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.5 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
Study: NCT00405418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Subcutaneous injection, once a day in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Detemir
Description: Subcutaneous injection, twice a day at breakfast and before dinner
Study: NCT04204161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T19/CAR-T22
Description: According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.The recommand dose is 1x10\^5/kg-2.5x10\^8/kg .
Study: NCT03358550

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Accommodation Measurement
Description: Accommodation was measured for different distances and light conditions.
Study: NCT03764514

Intervention type: DEVICE
Intervention: Spinal Cord Stimulator
Description: Permanent Implantation
Study: NCT03871530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate A
Description: PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate B
Description: PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate C
Description: PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate D
Description: PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate E
Description: PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL
Study: NCT00872209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% Ciprofloxacin Ear Drops
Description: 4 gtt BID for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% Ciprofloxacin Foam Otic Cipro
Description: 1 application, BID for 7 days
Study: NCT02849613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adipose Derived Stem Cells

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vehicle media
Study: NCT04566562

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain Imaging
Description: Magnetic Resonance Imaging (MRI) using diffusion weighted pseudo-continuous arterial spin labeling (DW-pCASL) .

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Testing
Description: Wide Range Assessment of Memory and Learning (WRAML 2) and Montreal Cognitive Assessment (MoCA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Biomarkers
Description: Inflammatory Markers
Study: NCT03871530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate F
Description: PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate G
Description: PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate H
Description: PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate I
Description: PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL
Study: NCT04291053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: standard treatment + Huaier Granule 20g po tid for 2weeks
Study: NCT00809367

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of Leukemia Cells
Description: Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
Study: NCT02088957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam intravenous solution
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/mL~* Route of Administration: Intravenous bolus use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam oral tablets
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid)~* Route of Administration: Oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin intravenous solution
Description: * Active Substance: Phenytoin~* Pharmaceutical Form: Solution for infusion~* Concentration: 50 mg/mL~* Route of Administration: Intravenous use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin oral tablets
Description: * Active Substance: Phenytoin~* Pharmaceutical Form: Tablet~* Concentration: Weight based~* Route of Administration: Oral use
Study: NCT01523067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasomera (PB1046)
Description: Single dose of Vasomera

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Placebo injection
Study: NCT00512655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fall prevention course
Description: Duration: 5 weeks, 2 sessions of 2 hours per week: 10 sessions in total.
Study: NCT02071290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet
Description: Four cycles of brief occlusion of bloodflow to the thigh (5 minutes) followed by reperfusion (5 minutes) using a pneumatic tourniquet~Remote Ischemic Conditioning

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pneumatic tourniquet
Description: Four cycles of brief occlusion of bloodflow to the thigh (5 minutes) followed by reperfusion (5 minutes) using a pneumatic tourniquet~Remote Ischemic Conditioning
Study: NCT02906826

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video game
Description: Video game operated by performing therapy correctly
Study: NCT03215862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: This is a Lactated Ringer's solution infusion before, during, and after the ERCP procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline 0.9% Infusion Solution Bag
Description: This is a Normal Saline solution infusion before, during, and after the ERCP procedure.
Study: NCT02370264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study: NCT03871530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate J
Description: PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL
Study: NCT03338296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin hydrochloride XR
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study: NCT00868153

Intervention type: DRUG
Intervention: Levonorgestrel IUS (Mirena , BAY86-5028)
Description: One group
Study: NCT04578353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The AquaPass System
Description: The AquaPass device is a capsule that creates relatively homogenous temperature around the patients' lower body, while controlling and maintaining at a low percentage the relative humidity within the capsule thus enabling controlled environment that enhances sweat rate.
Study: NCT01741805

Intervention type: OTHER
Intervention: Severe Asthma
Description: Demographic data, Spirometry, induced sputum, IgE, Aspergillus specific IgE
Study: NCT00874731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus 100 mg
Description: Part 1: A single oral dose of 100 mg ridaforolimus (10 x 10 mg tablets) was given on Day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus 40 mg
Description: Part 2 (optional): Ridaforolimus 40 mg (4 x 10 mg tablets) was received on a regimen of daily oral doses for 5 consecutive days followed by 2 days off-drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Part 1: A single oral dose of placebo (10 x placebo tablets) was given on Day 1.
Study: NCT00458081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: 20 mg once per day + slightly reduced calorie diet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once per day + slightly reduced calorie diet
Study: NCT00002622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: talc
Description: 4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talc
Description: 4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time
Study: NCT00953186

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: hyperbaric air
Description: air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HBOT
Description: 100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
Study: NCT02175641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Led Group Lifestyle Balance
Description: The intervention follows the Group Lifestyle Balance curriculum derived from the Diabetes Prevention Program and The intervention will be delivered by trained peer-specialists employed at the supportive housing agencies and supervised by the study team. Peer GLB is a 12-month group intervention that focuses helping people lose weight by improving people's diet and increasing their physical activity and consists of weekly core group sessions (3 mo.), bi-monthly transitional group sessions (3 mo.), and maintenance monthly sessions (6 mo.).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care Services
Description: The usual care condition encompasses the regular services offered at supportive housing agencies to help clients with their physical health and wellness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Services
Description: The usual care condition encompasses the regular services offered at supportive housing agencies to help clients with their physical health and wellness.
Study: NCT03822975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is \>225 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated Heparin
Description: Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is \>225 seconds.
Study: NCT01076777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
Study: NCT00479882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: simvastatin
Study: NCT03871530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate K
Description: PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate L
Description: PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate M
Description: PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinate N
Description: PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL
Study: NCT00292552

Intervention type: OTHER
Intervention: Novel endpoint determination
Description: Novel endpoint determination

Intervention type: OTHER
Intervention: Novel endpoint determination
Description: Novel endpoint determination

Intervention type: OTHER
Intervention: Novel endpoint determination
Description: Novel endpoint determination
Study: NCT05380154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A type for injection (Botulax®)
Description: Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®)
Description: Person in charge of dilution uses 0.9% sodium chloride injection solution to formulate the drug substance into 4U/0.1mL composite solution, and the investigator injects it into the test subjects.
Study: NCT01715233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Modified Docetaxel 40mg/m2 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 400mg/m2 on Day 1
Study: NCT00479882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524A
Description: Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524A
Description: Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet
Study: NCT01715233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 400mg/m2 on Day 1 Fluorouracil 1000mg/m2/day on Days 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (or Carboplatin) 40mg/m2 on Day 3
Study: NCT00479882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524A
Description: Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524A
Description: Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524B
Study: NCT00523640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of gemcitabine, capecitabine, and bevacizumab
Description: gemcitabine 1000 mg/m\^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
Study: NCT03969368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rPMS device
Description: Pelvic floor muscle contractions will be induced by the rPMS device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: Control group will undergo a pelvic floor muscle training
Study: NCT02212353

Intervention type: OTHER
Intervention: Observational study, not interventional

Intervention type: OTHER
Intervention: Observational study, not interventional

Intervention type: OTHER
Intervention: Observational study, not interventional